Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for Parkinson's disease

被引：19
|
作者：
Townsend, M [1 ]
MacIver, DH [1 ]
机构：
[1] Taunton & Somerset Hosp, Dept Cardiol, Taunton TA1 5DA, Somerset, England
来源：
HEART | 2004年 / 90卷 / 08期
关键词：
D O I：
10.1136/hrt.2004.036236
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A 63 year old man with a six year history of Parkinson's disease presented with signs of right heart failure following a knee replacement. Constrictive pericarditis was diagnosed and a radical pericardectomy performed. Six months later, the patient remained unwell with raised inflammatory markers. An inflammatory fibrotic reaction caused by cabergoline was diagnosed. He improved after cessation of cabergoline.
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease
    Hutton, JT
    Koller, WC
    Ahlskog, JE
    Pahwa, R
    Hurtig, HI
    Stern, MB
    Hiner, BC
    Lieberman, A
    Pfeiffer, RF
    Rodnitzky, RL
    Waters, CH
    Muenter, MD
    Adler, CH
    Morris, JL
    NEUROLOGY, 1996, 46 (04) : 1062 - 1065
  • [42] Effects of cabergoline on sleep benefits in Parkinson's disease: An actigraphic study
    Katayama, S.
    EUROPEAN JOURNAL OF NEUROLOGY, 2004, 11 : 113 - 113
  • [43] Pharmacodynamic and pharmacokinetic features of cabergoline - Rationale for use in Parkinson's disease
    Fariello, RG
    DRUGS, 1998, 55 (Suppl 1) : 10 - 16
  • [44] Treatment of Parkinson's disease and restless legs syndrome with cabergoline, a long-acting dopamine agonist
    Porter, MC
    Appiah-Kubi, LS
    Chaudhuri, KR
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2002, 56 (06) : 468 - 474
  • [45] Cabergoline versus ropinirole as add-on therapy in Parkinson's disease
    Unal, Z
    Boylu, E
    Orhan, S
    MOVEMENT DISORDERS, 2005, 20 : S96 - S96
  • [46] Efficacy and safety of high-dose cabergoline in Parkinson's disease
    Odin, P
    Oehlwein, C
    Storch, A
    Polzer, U
    Werner, G
    Renner, R
    Shing, M
    Ludolph, A
    Schüler, P
    ACTA NEUROLOGICA SCANDINAVICA, 2006, 113 (01): : 18 - 24
  • [47] Retroperitoneal fibrosis caused by treatment with pergolide in a patient with Parkinson's disease
    Kunkler, RB
    Osborn, DE
    Abbott, RJ
    BRITISH JOURNAL OF UROLOGY, 1998, 82 (01): : 147 - 147
  • [48] Study of cabergoline in treatment of childhood Cushing's disease
    Lila, Anurag R.
    Bandgar, Tushar
    Menon, Padmavathy S.
    Shah, Nalini S.
    HORMONE RESEARCH, 2009, 72 : 209 - 209
  • [49] Population pharmacodynamics (PD) of cabergoline (CAB), in patients with Parkinson's disease.
    Fullerton, T
    Forrest, A
    Collins, DA
    Narang, PK
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (02) : PII72 - PII72
  • [50] Clinical experience with cabergoline in patients with advanced Parkinson's disease treated with levodopa
    Marsden, CD
    DRUGS, 1998, 55 (Suppl 1) : 17 - 22
12345